L3VLUP
ProSign in

BCRX · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BCRXGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BCRX
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterBCRXGILD
Q3 20202 holders, $4.8m25 holders, $14.2bn
Q4 20203 holders, $33m27 holders, $13.4bn
Q1 20211 holders, $31m24 holders, $14.5bn
Q2 20213 holders, $88m18 holders, $14.9bn
Q3 20216 holders, $119m20 holders, $16.4bn
Q4 20214 holders, $79m20 holders, $16.8bn
Q1 20225 holders, $83m28 holders, $13.2bn
Q2 20224 holders, $60m26 holders, $13.6bn
Q3 20227 holders, $85m24 holders, $13.3bn
Q4 20228 holders, $111m32 holders, $21.1bn
Q1 20236 holders, $59m27 holders, $21.8bn
Q2 20234 holders, $53m24 holders, $20.7bn
Q3 20234 holders, $44m24 holders, $20.0bn
Q4 20232 holders, $15m22 holders, $21.5bn
Q1 20243 holders, $16m30 holders, $20.3bn
Q2 20243 holders, $30m28 holders, $18.5bn
Q3 20243 holders, $34m29 holders, $24.2bn
Q4 20242 holders, $23m28 holders, $25.9bn
Q1 20254 holders, $50m33 holders, $32.0bn
Q2 20257 holders, $170m27 holders, $30.9bn
Q3 20255 holders, $74m23 holders, $29.4bn
Q4 20256 holders, $138m25 holders, $34.3bn
Q1 20266 holders, $170m25 holders, $38.5bn
Q2 20267 holders, $187m26 holders, $34.2bn
BCRX

Biocryst Pharmaceuticals Inc

Holders
5
Reported value
$74m
Buyers
4
Sellers
0

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
23
Reported value
$29.4bn
Buyers
9
Sellers
14

Breadth -5 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2025

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only BCRX (5)

Brevan Howard Capital Management LP, Farallon Capital Management LLC, PDT Partners LLC, Two Sigma Advisers LP, Two Sigma Investments LP

Only GILD (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →